Cite

    Dodick, D. et al. (2017). A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. Journal of neurology, neurosurgery and psychiatry. 88 (5), p. e1. [Online].